
    
      Participants with wAMD were randomized and received a T&E or PRN regimen for 24 months. Mean
      Snellen BCVA and mean central macular thickness by OCT were examined at each visit. Any
      treatment-related adverse events, such as endophthalmitis, and systemic adverse events, such
      as stroke, were evaluated during the research.
    
  